Kilbourne E M
Epidemiology Program Office, Centers for Disease Control, Atlanta, GA 30333.
Epidemiol Rev. 1992;14:16-36. doi: 10.1093/oxfordjournals.epirev.a036085.
In late October 1989, over 1,500 cases of an unusual illness involving severe myalgia and striking peripheral eosinophilia were reported in the United States and several other countries. Other clinical manifestations included pulmonary involvement (interstitial infiltrates and pleural effusions), skin rash and edema, axonal polyneuropathy, perimyositis, and possible adverse neurocognitive effects. Because of the primary manifestations of the illness, it was named "eosinophilia-myalgia syndrome" (EMS) by the Centers for Disease Control. Epidemiologic studies clearly linked illness to the ingestion of tryptophan produced by a single manufacturer in Japan, and the time course of the epidemic was most consistent with its being caused by a product contaminant. Epidemiologic analysis of plant operating conditions and data obtained from chemical analyses of case- and control-associated lots implicated 1,1'-ethylidene-bis(tryptophan) (EBT) as a candidate for the compound that causes EMS. However, the etiologic significance of EBT is still uncertain. Factors found to increase a person's risk for EMS included higher tryptophan dose and older age. Although cases occurred predominantly in women and patients had frequently been taking other medications concurrently with tryptophan, sex and use of several categories of other medications were not shown to influence the risk of illness. Few patients recovered rapidly and fully from the disease. Many were treated with glucocorticoid medications, and although they may have benefited from therapy in the short term, the development of chronic sequelae of EMS appears not to have been prevented. Public health practitioners currently depend on the reports of alert clinicians to detect this type of outbreak. In this case, state and federal government epidemiologists, once they were notified, were able to develop substantial basic information about the epidemic in a relatively short time. Control measures were introduced rapidly, effectively stopping the epidemic.
1989年10月下旬,美国和其他几个国家报告了1500多例涉及严重肌痛和明显外周嗜酸性粒细胞增多的异常疾病病例。其他临床表现包括肺部受累(间质性浸润和胸腔积液)、皮疹和水肿、轴索性多神经病、肌束膜炎以及可能的不良神经认知影响。由于该疾病的主要表现,美国疾病控制中心将其命名为“嗜酸性粒细胞增多性肌痛综合征”(EMS)。流行病学研究明确将该疾病与摄入日本一家制造商生产的色氨酸联系起来,并且疫情的时间进程与其由产品污染物引起最为相符。对工厂运营条件的流行病学分析以及从病例组和对照组相关批次的化学分析中获得的数据表明,1,1'-亚乙基双(色氨酸)(EBT)是导致EMS的化合物的候选物。然而,EBT的病因学意义仍不确定。发现增加一个人患EMS风险的因素包括色氨酸剂量较高和年龄较大。尽管病例主要发生在女性中,并且患者经常在服用色氨酸的同时还服用其他药物,但性别和几类其他药物的使用并未显示会影响患病风险。很少有患者能迅速完全康复。许多患者接受了糖皮质激素药物治疗,尽管他们可能在短期内从治疗中受益,但EMS慢性后遗症的发展似乎并未得到预防。公共卫生从业者目前依赖警惕的临床医生的报告来发现此类疫情。在这种情况下,州和联邦政府的流行病学家一旦接到通知,就能在相对较短的时间内收集到有关该疫情的大量基本信息。迅速采取了控制措施,有效地阻止了疫情的蔓延。